One company dominates with an approved therapy, while the other bets on in vivo innovation. See how their financials and risk ...

Its revolutionary CASGEVY treatment could be a sign of what's to come.

It has also aggressively invested in gene editing, including its 2025 acquisition of cardiovascular disease gene-editing ...

Are there significant gains ahead for one (or both) of these innovative biotechs?

Finding a quality mid-cap stock to invest in can lead to huge returns for investors down the road. These are the types of companies that are still in their early growth stages and that can possess ...

CRISPR Therapeutics AG (CRSP) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...